Lillys Retatrutide - GLP-1/GIP/Glucagon multi-agonist - helps patients lose more than 24% of their body weight in just 48 weeks
UK practice involves risk-based assessment considering medication type, dosage, gastrointestinal symptoms, procedure complexity, and individual patient factors rather than universal cessation
We supply our peptides as lyophilised powders because it vastly increases their stability and structural integrity during transit and storage
The package insert says a pound or two per week is what we should be shooting for, Dr
If sulfur burps or other GI symptoms interfere with your progress, clinicians can adjust dosing, modify timing, or discuss combination therapies designed to manage side effects while maximizing weight loss results
However, GLP-1 Treatments, Semaglutide or Tirzepatide isn't one of those quick-fix solutions